---
layout: post
title: "Bristol Myers Products Inc.; Proposal To Withdraw Approval of a New Drug Application for Bufferin (Aspirin) Tablets; Opportunity for a Hearing"
date: 2026-02-05 19:01:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-25516
original_published: 2022-11-23 00:00:00 +0000
significance: 8.00
---

# Bristol Myers Products Inc.; Proposal To Withdraw Approval of a New Drug Application for Bufferin (Aspirin) Tablets; Opportunity for a Hearing

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 23, 2022 00:00 UTC
**Document Number:** 2022-25516

## Summary

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of a new drug application (NDA) for Bufferin (aspirin) tablets, for which Bristol Myers Products Inc., 1350 Liberty Ave., Hillside, NJ 07205 is the last holder of record, and is announcing an opportunity for the holder of the NDA to request a hearing on this proposal. The basis for the proposal is that the holder of the NDA has repeatedly failed to file required annual reports for this NDA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/23/2022-25516/bristol-myers-products-inc-proposal-to-withdraw-approval-of-a-new-drug-application-for-bufferin)
- API: https://www.federalregister.gov/api/v1/documents/2022-25516

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
